PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
User tried DIY Dutasteride Mesotherapy for hair loss due to unsatisfactory Finasteride results. Used mesotherapy injection gun and liquid dutasteride for better results and fewer side effects.
The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.
Exploring the potential of using Verteporfin to grow follicles in combination with microneedling, as well as the cost of administering a single injection and the possibility of combining it with minoxidil.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
The user has been using topical minoxidil with tretinoin for 9 months without much regrowth and suspects finasteride is responsible for any improvement. They are inquiring about tests to determine response to topical minoxidil and seeking advice on switching to oral minoxidil, including potential side effects and monitoring requirements.
The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
A user started taking finasteride 1mg/day for hair loss but hasn't seen results yet. They also take vitamins and asked about adding minoxidil and the effectiveness of LLLT.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.